FDA approved trastuzumab for use with other drugs in adjuvant treatment of women with early-stage, node-positive, HER2-overexpressing breast cancer
| | | |

FDA approved trastuzumab for use with other drugs in adjuvant treatment of women with early-stage, node-positive, HER2-overexpressing breast cancer

On Nov. 16, 2006, the U.S. Food and Drug Administration (FDA) approved Genentech’s trastuzumab (Herceptin) for use with…